VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reissued their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE – Free Report) in a research report released on Wednesday morning, Benzinga reports. The firm currently has a $5.75 target price on the stock. VYNE Therapeutics Price Performance Shares of VYNE opened at $2.25 on Wednesday. VYNE Therapeutics has a 1 year low […]
More Stories
Fauci Refuses to Appear Before 2nd Senate Panel After Contempt Vote
By Tom Ozimek Dr. Anthony Fauci has declined a request to appear voluntarily before a second Senate panel, days after...
HHS Report on Alleged Pediatric Gender-Treatment Fraud: 5 Key Takeaways
By Stacy Robinson A report released Aug. 13 by the Department of Health and Human Services (HHS) has shined a...
North Korea Threatens Stronger Deterrence Ahead of US–South Korea Military Drills
By Victoria Friedman Pyongyang has denounced the upcoming annual joint U.S.–South Korean military drills on the peninsula, calling them provocative...
Trump Says He’ll Declare the Hormuz Strait a US Territory ‘Pretty Soon’
By Emel Akan President Donald Trump announced on Friday his intention to declare the Strait of Hormuz a U.S. territory,...
Hurricane Watch Issued for Hawaii’s Big Island as Tropical Storm Lala Forms
By Savannah Hulsey Pointer A hurricane watch has been issued for the Big Island of Hawaii as Tropical Storm Lala...
Earnings Are Up Over 50% So Far
By Louis Navellier Through last Friday, 88% of the S&P 500 companies have announced second-quarter results. According to FactSet Earnings...